Radiosensitivity is an acquired vulnerability of PARPI-resistant BRCA1-deficient tumors

Marco Barazas, Alessia Gasparini, Yike Huang, Asli Küçükosmanoglu, Stefano Annunziato, Peter Bouwman, Wendy Sol, Ariena Kersbergen, Natalie Proost, Renske de Korte-Grimmerink, Marieke van de Ven, Jos Jonkers, Gerben R. Borst, Sven Rottenberg

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The defect in homologous recombination (HR) found in BRCA1-associated cancers can be therapeutically exploited by treatment with DNA-damaging agents and PARP inhibitors. We and others previously reported that BRCA1-deficient tumors are initially hypersensitive to the inhibition of topoisomerase I/II and PARP, but acquire drug resistance through restoration of HR activity by the loss of end-resection antagonists of the 53BP1/RIF1/REV7/Shieldin/CST pathway. Here, we identify radiotherapy as an acquired vulnerability of 53BP1; BRCA1-deficient cells in vitro and in vivo. In contrast to the radioresistance caused by HR restoration through BRCA1 reconstitution, HR restoration by 53BP1 pathway inactivation further increases radiosensitivity. This highlights the relevance of this pathway for the repair of radiotherapy-induced damage. Moreover, our data show that BRCA1-mutated tumors that acquire drug resistance due to BRCA1-independent HR restoration can be targeted by radiotherapy.
Original languageEnglish
Pages (from-to)452-460
JournalCancer Research
Volume79
Issue number3
DOIs
Publication statusPublished - 1 Feb 2019
Externally publishedYes

Cite this

Barazas, M., Gasparini, A., Huang, Y., Küçükosmanoglu, A., Annunziato, S., Bouwman, P., ... Rottenberg, S. (2019). Radiosensitivity is an acquired vulnerability of PARPI-resistant BRCA1-deficient tumors. Cancer Research, 79(3), 452-460. https://doi.org/10.1158/0008-5472.CAN-18-2077